LENSAR, Inc.

LNSR Healthcare Medical Devices

LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024. In the quarter to June 2026, revenue grew 18.4%, EPS grew 291.7% and free cash flow grew 96.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

5.80 0.23 −3.81%
Market cap
$74.1M
P/E
2.0×
Fwd P/E
7.1×
Dividend yield
—
F-score
3/9
Altman Z
−2.84
Beneish M
−4.30
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 3 3

+8 more TTM periods

ROE
(851.75%) (517.96%) 324.05% 3,251.75%
ROA
49.58% 42.24% (49.78%) (77.94%)
ROIC
(379.01%) 0.00% 0.00% 0.00%
Return on Tangible Assets
124.67% 117.31% (511.49%) (556.47%)
Average Days of Receivables
37.37 30.97 39.83 36.42
Free Cash Flow per Share
(0.60) (1.00) (1.25) (0.99)
Free Cash Flow
(7.40) (12.16) (14.91) (11.88)
Capital Expenditures
(0.11) — (0.08) (0.09)
Other line items
Cash ROIC
(26.01%) (50.09%) 185.47% 131.42%
Accounts Receivable Turnover
10.80 9.80 9.38 11.51
Accounts Payable Turnover
2.77 3.51 2.51 3.41
Inventory Turnover
1.41 1.63 1.90 1.79
Average Days of Payables
131.23 117.65 221.26 169.55
Days of Inventory on Hand
291.59 269.15 250.85 236.04
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
8.83% 9.48% 9.62% 9.57%
Selling, General and Administrative Expense of Revenue
51.47% 63.32% 77.28% 70.44%
Share Based Compensation of Revenue
4.58% 5.51% 5.38% 4.96%
Operating CF/Net income
(0.21) (0.41) 0.43 0.23
Depreciation/Fixed assets
10.09 9.68 8.56 7.58
Capex/Depreciation
(0.02) 0.00 (0.02) (0.02)
Revenue per Share
4.90 4.75 4.89 4.91
Operating CF per Share
(0.59) (1.00) (1.24) (0.98)
Capex per Share
(0.01) 0.00 (0.01) (0.01)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates